With an estimated 21% of horses over the age of 15 affected by pituitary pars intermedia dysfunction (PPID),1 ongoing monitoring plays a critical role in managing this progressive condition. To further support veterinarians in evaluating treatment response, Boehringer Ingelheim has added a recheck component to its IDPPID testing program.

Starting with the current spring 2026 testing period, eligible horses newly diagnosed with PPID and undergoing treatment with Prascend (pergolide tablets) may be reevaluated through the program. This update enables veterinarians to assess changes in endocrine health alongside clinical signs, helping inform next steps in disease management. Veterinarians can contact their Boehringer territory manager with questions or for more information.

“PPID is a progressive disease,” says Steve Grubbs, DVM, PhD, Dipl. ACVIM, technical manager, Equine, Boehringer Ingelheim. “By offering a recheck, we are providing veterinarians with additional valuable information to help guide treatment protocols, while continuing to build our understanding of PPID and its progression.”

Since the IDPPID program’s inception in 2013, more than 65,000 horses have been tested,2 resulting in horses being diagnosed and subsequently treated for PPID.

Besides rechecking horses with PPID via adrenocorticotropic hormone (ACTH), insulin, and glucose testing, Grubbs recommends continuing to monitor changes in clinical signs observed at initial diagnosis. These signs can include changes in attitude, decreased performance, delayed hair coat shedding, and loss of topline muscle in the early stages. If the condition is more advanced, recurrent infections, exercise intolerance, and generalized muscle atrophy might be present.

The spring testing period is currently open through June 9, 2026. The fall testing period runs Aug. 18–

Oct. 13. For more details, visit IDPPID.com.

1Grubbs ST, Neal DL and Keefe TJ. Epidemiological characteristics of horses with PPID at initial diagnosis. Boehringer Ingelheim Animal Health USA Inc., St. Joseph, Mo., and Colorado State University, Fort Collins, Co. 2020.

2IDPPID Testing Program, 2013-2025. Data on file.